CI	M Pharmaceuticals, Inc. Subject ID 044 -	1 _	
	Subject Initials		
	E	ligib	ility
Inc	clusion Criteria (all answers must be YES to be included in the trial)	Yes	No
1	Age 18-45 years, inclusive	1	□ 0
2	Willingness to submit to diagnostic machine testing	1	□ 0
3	Male or non-pregnant, non-lactating female. Women of reproductive potential must be practicing adequate contraception (e.g., intrauterine device or double barrier device such as a diaphragm or condom plus spermicide). Abstinence is not considered to be an acceptable method of contraception. Additionally, women of reproductive potential must have a negative urine pregnancy at screening and prior to enrollment	1	□ 0
4	In good health as determined by medical history and physical examinations	1	□ 0
5	Capable of understanding and complying with the protocol and has signed the informed consent document	1	□ o
Ex	clusion Criteria (all answers must be NO to be included in the trial)	Yes	No
1	Pregnant or lactating females	1	□ o
2	History of anaphylaxis	1	□ 0
3	History or presence of hepatitis	1	□ 0

M Pharmaceuticals, Inc.		Subject ID 044 - 1
		Subject Initials
		Demographics/Medical Histo
Demographics Description		
Sex: Race: \square_1 Male \square_1 Cauc \square_2 Female \square_5 Oth	casian [] : er (specify):_	₂ Black ☐ ₃ Hispanic ☐ ₄ Asian
		Date Informed Consent Signed ://
Drognonov toot		
Pregnancy test Result:	□ ₀ Negativ	ve
Medical History		
Body System	Normal	Abnormal (describe)
Neuro	О	
HEENT	О	
Heart	О	
Lungs	О	
Abdomen	О	
Musculoskeletal	О	
Peripheral Vascular	О	
Skin	□ o	

1 Pharmaceutica	als, Inc.		Sı	ubject ID 044 - 1
				Subject Initials
				Physical Examina
		Study Day 1	1	Study Day 2
Body System	Normal	Abnormal (describe)	Normal	Abnormal (describe)
Neurological	o		□ o	☐ 1 Unchanged from Study Day 1
HEENT	o		o	☐ 1 Unchanged from Study Day 1
Heart	o		o	☐ 1 Unchanged from Study Day 1
Lungs	o		o	☐ 1 Unchanged from Study Day 1
Abdomen	o		□ o	☐ 1 Unchanged from Study Day 1
Musculoskeletal	o		o	☐ 1 Unchanged from Study Day 1
Peripheral Vascular	o		□ o	☐ 1 Unchanged from Study Day 1
Skin	□ o		□ o	

Additional Findings:

☐ 1 Unchanged from Study Day 1

 \square ₁ Unchanged from Study Day 1

CM Pharmaceuticals, Inc.	Subject ID 044 - 1
	Subject Initials
	Laboratory

	Study Day 1	Study Day 2
Name of Lab		
Lab test	Result	Result
	☐ ₁ Not Done	☐ ₁ Not Done
Sodium		
Potassium		
Chloride		
BUN		
Creatinine		
Total Protein		
Albumin		
Direct bilirubin		
Total bilirubin		
ALT/SGPT		
AST/SGOT		
LDH		
WBC		
Neutrophils		
Eosinophils		
Basophils		
Lymphocytes		
Monocytes		
Hct%		
Hgb		
Platelets		
INR		
PT		
PTT		

CM P	Pharmaceutica	als, Inc.					Subject ID	044 - 1 [1		
									- - -		
							Subject		<u>.</u>		
		;	Stud		/ /_ dd y		Evaluation	ons and Dos	sing		
	Baseline Vital Signs										
	Time (24 Hour)	Ten		HR (per minute)	RR (per mir		BP (syst/dia)	O ₂ Sat (%)			
	(24 Hour) (°F)						1				
	Weight			Height		Hea	Ith Question	nnaire Score	1		
	Kg			inches			Pre	Post			
	Cohort			Infusion Period #1			Infusion Period # 2				
	1 🗆		<u> </u>	☐ 1 Bottle 1.25 mg/kg ☐ 1 Bottle			Bottle 1	1.25 mg/kg			
	2 🗌		2	□ ₂ Bag 0.65 mg/kg			☐ ₂ Bag 0.65 mg/kg				
				□₃ Bag, other 0			Bag, other				
			A	Amount PROD infused			Amount PROD infused				
	☐ Other			mg			•	mg			

	Study Day 1	Vital Signs
		Subject Initials
CM Pharmaceuticals, Inc.		Subject ID 044 - 1

Timepoint	Time (24 Hour)	HR (per min)	BP (syst/dia)	O ₂ Sat (%)
- 5 minutes	:		1	
0 minutes	:		1	
5 minutes	:		1	
10 minutes	:		1	
15 minutes	:		1	
20 minutes	:		1	
25 minutes	:		1	
30 minutes	:		1	
35 minutes	:		1	
40 minutes	:		1	
45 minutes	:		1	
50 minutes	:		1	
55 minutes	:		1	
60 minutes			1	
65 minutes	:		1	
70 minutes	:		1	
End of Infusion Period #2	:			
1 hour after Infusion Period #2	:		1	

CM Pharmaceuticals, Inc. Subject ID 044 - 1										
					Subject	t Initials 🔲 🔲 🗌				
					Concomit	ant Medications				
o No	□ ₀ None									
	Medication	Dose	Unit	Route	Date (mm / dd / yy)	Time (24 Hour)				
1					/	:				
2						·				
3					/	:				
4					/	:				
5					//	:				
6					/	:				
7					//	:				
8					//	:				
9					//	:				
10						:				
11					//	:				
12						:				
		_		_	☐ Check if	subsequent pages				

CN	1 Pharmaceuticals, Inc.						
		F	Report all Seriou IMMED	is Adverse Even NATELY	ts	Subject	id 044 - 1 [
						Subje	ct Initials 🔲 🔲
							Adverse Events
] _o None						
_	Event Description		Onset	Resolution	Severity	Relationship to PROD	Actions taken (✓ all applicable)
		Date (mm/dd/yy)	//	//	☐ ₁ Mild ☐ ₂ Moderate	☐₁ Unrelated ☐₂ Possibly	☐₀ None ☐₁ Treatment
		Time (24 hour)	:	: □ ₁ Continuing	☐ ₃ Severe ☐ ₄ Life-threatening	☐₃ Probably ☐₄ Definitely	☐ 2 PROD stopped ☐ 3 Discontinued trial ☐ 4 SAE Reported
		Date (mm/dd/yy)	//	//	☐ 1 Mild ☐ 2 Moderate	Unrelated Possibly	☐ 0 None ☐ 1 Treatment
2	2	Time (24 hour)	:	: □ ₁ Continuing	☐ ₃ Severe ☐ ₄ Life-threatening	☐ ₃ Probably ☐ ₄ Definitely	PROD stopped 3 Discontinued trial 4 SAE Reported
		Date (mm/dd/yy)	//	//	☐ 1 Mild ☐ 2 Moderate	Unrelated Possibly	☐₀ None ☐₁ Treatment
	3	Time (24 hour)	:	: □ ₁ Continuing	☐₃ Severe ☐₄ Life-threatening	☐ ₃ Probably ☐ ₄ Definitely	☐ 2 PROD stopped ☐ 3 Discontinued trial ☐ 4 SAE Reported
		Date (mm/dd/yy)	//	//	☐ 1 Mild ☐ 2 Moderate	☐₁ Unrelated ☐₂ Possibly	☐₀ None ☐₁ Treatment
	1	Time (24 hour)	:	: □ ₁ Continuing	☐₃ Severe ☐₄ Life-threatening	☐ ₃ Probably ☐ ₄ Definitely	☐₂ PROD stopped ☐₃ Discontinued trial ☐₄ SAE Reported
ī	nvestigator's Signature					Date ☐₁ Check if su	bsequent pages

M Pha	armaceuticals,	Inc			S	ubject ID 044	4 - 1 🖂 🗆
						Subject Initial	
		Stud		ıy 2	///	-	Completio
	ly Completion	n/Termination					
Vita	Time (24 Hour)	Temp (°F)		HR per minute)	RR (per minute)	BP (syst/dia)	O ₂ Sat
	:					1	
	he subject con , please compl			☐ ₁ Yes all applical			
Re	ason for disco	ntinuation		Date n / dd / yy			
1	1 Adverse Event		/	/	event:		
2	☐₂ Withdrew consent		/	/	reason:		
П3			/	/	reason:		
<u> </u>	☐ ₄ Right-to-left cardiac shunt		//		-		
<u></u> 5	Other		/	//_specify:			
Was	mary of Proto the protocol fo , please compl	ollowed withou ete the followi	ıt devi		□₁Yes □₀ ble)	No	
	Depar	rtures					
1	Entrance Crite	eria not met		specify:			
2	PROD not ad	ministered full	ly	reason:			
☐₃ Images not obtained			explain:				
Safety data not obtained or not collected at scheduled time point			explain:				
□ ₅ Other			specify:				